Q-omics provides the consensus-scored MYO5A profile across patient tissues and cancer cell-line models. MYO5A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MYO5A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MYO5A protein abundance shows 28,419 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, HNSC, and GBM as cancer lineages where MYO5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO5A survival associations across molecular data types. MYO5A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO5A RNA expression–survival associations across cancer types. High MYO5A expression shows unfavorable associations in BLCA, STAD, MESO and ACC, but favorable associations in KIRC and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MYO5A RNA expression.
This table summarizes MYO5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO5A shows lower tumor expression in COAD and higher tumor expression in HNSC, LIHC, KICH, CHOL and BLCA. The HNSC box plot shows higher MYO5A RNA expression in tumor versus normal tissue (log2 FC = +2.235, t-test p < 0.001).
This table shows molecular features associated with MYO5A in patient tissues and cancer cell lines. In patient samples, MYO5A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
